Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Solid Cancers 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × parsatuzumab × Clear all
NCT00909740 2022-12-12

A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors

Genentech, Inc.

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

NCT01075464 2016-11-02

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
64 enrolled

Solid Cancers

NCT01366131 2016-11-02

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Genentech, Inc.

Phase 2 Completed
104 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01399684 2016-08-26

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Genentech, Inc.

Phase 2 Completed
127 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡